Eric H. Yang, MD

Dr Eric H. Yang | Image Credit: UCLA Health

Eric H. Yang, MD, is an associate clinical professor of medicine and the founder and director of the cardio-oncology program at the University of California, Los Angeles.

Articles by Eric H. Yang, MD

Emerging Treatment Strategies Aim to Balance Cardiac Safety, Effective Breast Cancer Care: Eric H. Yang, MD

ByBrooke McCormick,Eric H. Yang, MD

January 9th 2026

Multidisciplinary care helps manage cardiac risks in breast cancer, allowing patients to continue treatment safely, says Eric H. Yang, MD.

Cardio-Oncology Collaboration Could Reduce Cardiovascular, Breast Cancer Risks: Eric H. Yang, MD

ByBrooke McCormick,Eric H. Yang, MD

January 2nd 2026

Eric H. Yang, MD, emphasizes the need for collaboration and interventions to protect patients’ hearts during breast cancer treatment.

Driving Progress Through Collaboration at SABCS

ByMaggie L. Shaw,Brooke McCormick,Justin Drake, PhD,Xiaotong Li, PhD, MS,Steven Manobianco, MD,Debra Patt, MD, PhD, MBA, MPH,Eric H. Yang, MD

December 18th 2025

The San Antonio Breast Cancer Symposium fosters collaboration among experts, enhancing research and treatment strategies for breast cancer's complex landscape.

Cardiotoxicity Remains a Concern as Breast Cancer Survival Rates Improve: Eric H. Yang, MD

ByBrooke McCormick,Eric H. Yang, MD

December 12th 2025

Eric H. Yang, MD, warns that lifetime cardiovascular risk for patients with breast cancer may exceed the general population as life expectancies grow, emphasizing the need for early intervention.

Eric H. Yang, MD

Articles by Eric H. Yang, MD

Emerging Treatment Strategies Aim to Balance Cardiac Safety, Effective Breast Cancer Care: Eric H. Yang, MD

Cardio-Oncology Collaboration Could Reduce Cardiovascular, Breast Cancer Risks: Eric H. Yang, MD

Driving Progress Through Collaboration at SABCS

Cardiotoxicity Remains a Concern as Breast Cancer Survival Rates Improve: Eric H. Yang, MD

Latest Updated Articles

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer